GlassScriptPhysician profile
James Neumann Childs
NPI 1023150083
$19,645.72
in general payments reported to CMS, 2019-2025
36 companies · $3,183 in 2025
The $3,183 reported for 2025 was more than what 85% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,125 · 2020: $1,607 · 2021: $2,361 · 2022: $3,101 · 2023: $3,950 · 2024: $3,320 · 2025: $3,183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,892 · Consulting Fee: $350 · Education: $210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,892.32 |
| Consulting Fee | $350.00 |
| Education | $209.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,590.75 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Mayne Pharma Commercial LLC | $2,123.28 | 2019-2025 | |
| Amgen INC. | $1,269.80 | 2019-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $1,193.67 | 2019-2025 | |
| Incyte Corporation | $1,071.51 | 2021-2025 | Opzelura, Opzelura |
| Abbvie INC. | $973.22 | 2021-2025 | Skyrizi, Rinvoq |
| Lilly USA, LLC | $973.14 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Galderma Laboratories, L.P. | $925.49 | 2019-2025 | Aklief, Nemluvio, Oracea |
| Almirall LLC | $900.99 | 2019-2025 | Seysara, Klisyri |
| Medimetriks Pharmaceuticals, INC. | $859.66 | 2019-2025 | Clindacin Etz, Neo-Synalar, Genadur |
| Sun Pharmaceutical Industries INC. | $823.28 | 2019-2025 | Winlevi, Absorica Ld, Ilumya |
| Pfizer INC. | $589.52 | 2019-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $582.56 | 2019-2025 | Jublia, Arazlo, Duobrii |
| Dermavant Sciences, INC. | $572.93 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $567.81 | 2023-2025 | Zoryve |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $516.34 | 2019-2024 | Dupixent, Libtayo |
| Leo Pharma INC. | $477.64 | 2019-2024 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $461.32 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $287.12 | 2020-2025 | |
| Vyne Pharmaceuticals INC. | $284.06 | 2020-2021 | |
| Encore Dermatology INC. | $282.13 | 2019-2020 | |
| Organon LLC | $273.49 | 2025 | Vtama |
| Ucb, INC. | $233.45 | 2019-2025 | Bimzelx, Cimzia |
| Journey Medical Corporation | $136.20 | 2019-2023 | |
| Paratek Pharmaceuticals, INC. | $124.99 | 2021 | |
| Epi Health, LLC | $114.47 | 2019-2021 | |
| Celgene Corporation | $92.39 | 2019 | |
| Botanix Sb INC | $88.06 | 2025 | Sofdra |
| Hill Dermaceuticals, INC. | $60.00 | 2024 | Tolak |
| Strata Skin Sciences, INC. | $37.21 | 2019-2022 | |
| Elekta, INC. | $36.50 | 2024 | Elekta Medical Linear Accelerator |
| Glenmark Therapeutics INC. | $35.00 | 2019 | |
| Mission Pharmacal Company | $31.77 | 2019-2020 | |
| Tactile Systems Technology INC | $24.91 | 2019 | |
| Dermira, INC. | $19.44 | 2020 | |
| Nabriva Therapeutics, Plc | $11.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Childs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.